AXO-LENTI-PD: POTENTIALLY TURNING BACK THE CLOCK FOR PATIENTS WITH PARKINSON’S DISEASE
AXO-Lenti-PD achieved up to 10-fold increases in dopamine + L-Dopa production and increased AADC activity compared to ProSavin ® (OXB-101)
Watch the following video of the older ProSavin treatment
• Cohort 2 (n=2 evaluable patients): Positive 6-month data demonstrating 21-point mean improvement from baseline in UPDRS III “OFF” score
• Cohort 3 (4.2 x 107 TU*) is three times more than Cohort 2 (1.4 x 107 TU*) *Target dose
• Sio plans to move to the third higher dose cohort in the study after which it expects to initiate the randomised, sham-controlled part of the SUNRISE-PD Phase 2 study in 2022
• Sales of products to treat Parkinson’s disease in the 7 major markets reached $3.1bn in 2016 and is forecast tovreach $8.4bn by 2026
Thursday, October 21, 2021 Poster Presentation Details:
Presentation Title: Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson’s Disease: Efficacy, Safety, and Tolerability Data up to 24 Months Poster Number: P254 Presenting Author: Gavin Corcoran, MD, Chief R&D Officer of Sio Gene Therapies
A poster review of patient-level data up to 24 months from the Phase 1/2 study of AXO-Lenti-PD gene therapy for the treatment of Parkinson’s disease.
News 
Market Data 
Discover 
